Good news about Alzheimer’s

Summary of Good news about Alzheimer’s

by Vox

26m•September 16, 2026
Listen to Episode

Overview of Good news about Alzheimer’s

This Vox segment explains why Alzheimer’s research has long been so frustrating, then shifts to the recent reasons for optimism. The episode traces the history of the disease’s dominant theory — that amyloid plaques drive Alzheimer’s — the failures and controversy around plaque-clearing drugs, and the revelations of fraudulent research that may have distorted the field for years. It then highlights the current “good news”: the first FDA-approved treatments that can modestly slow decline, a more diverse pipeline of future therapies, improved early detection, and even some speculative but intriguing work on possible reversal.

Why Alzheimer’s has been so hard to treat

A disease that attacks identity

  • Alzheimer’s is described as uniquely devastating because it doesn’t just affect memory — it gradually erodes a person’s sense of self.
  • As the disease progresses, people can lose:
    • short-term memory
    • recognition of loved ones
    • orientation in familiar places
    • independence and relationships

Why it became such a major problem

  • Historically, Alzheimer’s was rarer because fewer people lived to the ages when it typically develops.
  • As medicine improved and people lived longer, Alzheimer’s became far more common.
  • Today, it affects roughly:
    • 7 million Americans
    • 50 million people worldwide

The amyloid hypothesis and the long research detour

The original theory

  • Alzheimer’s was first defined by Alois Alzheimer over 100 years ago through two hallmark brain findings:
    • plaques made of amyloid protein
    • tangles made of tau protein
  • In the late 20th century, the amyloid cascade hypothesis became the dominant theory:
    • amyloid buildup triggers a chain reaction
    • that chain reaction eventually leads to dementia

Why the field focused so heavily on amyloid

  • The logical next step was to remove the plaques.
  • Researchers and drug companies invested heavily in plaque-clearing treatments and even vaccines.
  • These efforts often succeeded in removing amyloid — but did not meaningfully improve patients’ symptoms.
  • Some treatments also caused serious side effects.

The investigative scandal

  • Science Magazine journalist Charles Piller describes how a key study that boosted interest in a specific amyloid subtype, amyloid-beta star 56, was based on apparently doctored images.
  • That paper was later retracted.
  • Piller argues that tens of billions of dollars may have been spent chasing a hypothesis that, while not necessarily wrong, was overemphasized and may have crowded out other promising approaches.

The good news: what has changed recently

1) There are now FDA-approved treatments

  • Doctors now have two approved drugs to offer patients with early symptomatic Alzheimer’s:
    • lecanemab
    • donanemab
  • These drugs:
    • target amyloid plaques
    • can slow cognitive decline
    • do not cure or reverse the disease
  • The key point: for a long time, there was nothing to offer patients except hope and support.

2) The pipeline is broader and more promising

Researchers are no longer betting only on amyloid. New work is exploring:

  • Tau-targeting treatments
  • Inflammation-related mechanisms
  • Vascular health and blood flow
  • Possible combination therapies, similar to how cancer is treated with multiple approaches

Early results in some tau-related trials are described as encouraging, though still preliminary.

3) Early detection is improving

  • Because there are now treatments, scientists are investing more in identifying Alzheimer’s earlier.
  • Blood tests and other tools may help detect elevated risk before symptoms appear.
  • Earlier detection could allow:
    • earlier treatment
    • lifestyle changes
    • better planning and intervention

4) GLP-1 drugs may offer preventive potential

  • Drugs originally used for weight loss and diabetes are being investigated for possible Alzheimer’s prevention.
  • The logic:
    • better metabolic and vascular health may reduce dementia risk
    • weight loss can lower blood pressure and cardiovascular strain
  • This remains theoretical, but the Alzheimer’s Association is investing heavily in research on this link.

Could Alzheimer’s eventually be reversed?

Still out of reach, but no longer unthinkable

  • Full reversal is not currently available.
  • But several scientists think stopping progression — and possibly reversing some symptoms — may be possible in the future.

The controversial China surgery

  • The episode discusses experimental Chinese surgeries that reportedly create a drainage pathway in the brain to help clear amyloid and tau.
  • Videos showing dramatic before-and-after changes have generated excitement and skepticism.
  • Important caveats:
    • the videos may not be reliable evidence
    • the scientist behind the approach has reportedly been detained by Chinese authorities
    • the surgery has been restricted outside clinical trials
  • Researchers in the U.S. and elsewhere are trying to replicate the work before drawing conclusions.

Main takeaways

  • Alzheimer’s research was dominated for decades by the amyloid hypothesis.
  • That focus produced expensive failures and may have delayed broader thinking.
  • The field is now becoming more open and more complex, with attention shifting to:
    • tau
    • inflammation
    • vascular health
    • combination therapies
    • earlier detection
  • For the first time in a long time, there is real momentum:
    • approved treatments
    • a stronger drug pipeline
    • possible preventive strategies
  • The long-term hope remains the same: not just slowing Alzheimer’s, but eventually preserving — or restoring — the identity it steals.